Company News-宜明昂科英文

2026-06-01

ASCO 2026 | ImmuneOnco Presents Poster on Palverafusp Alfa (IMM2510) for IO-Treated Advanced Sq-NSCLC, Overcoming Resistance with Durable Efficacy and Safety

This marks the fourth consecutive year that IMM2510 has been featured at ASCO, the premier global oncology conference, further validating the robust global R&D capabilities and sustained potential of this blockbuster bispecific therapy.

2026-05-19

ImmuneOnco Initiates Phase II Trial of Amulirafusp Alfa (IMM0306) for SLE with First Patient Dosed

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces First Patient Enrolled in Phase II Randomized Controlled Study of IMM0306 for the Treatment of Systemic Lupus Erythematosus

2026-05-12

ImmuneOnco's Autoimmune Pipeline Achieves Another Breakthrough: IND Application for Amulirafusp Alfa (IMM0306) in Primary Sjögren's Syndrome Officially Approved

ImmuneOnco Secures IND Approval for amulirafusp alfa (IMM0306) in Primary Sjögren's Syndrome

2026-04-27

A National Investigators' Meeting for the Phase III Clinical Study of ImmuneOnco's Amulirafusp Alfa (IMM0306) in Relapsed/Refractory Follicular Lymphoma Was Successfully Convened

A National Investigators' Meeting for the "Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study of IMM0306 for Injection (Amulirafusp Alfa) in Combination with Lenalidomide versus Placebo in Combination with Lenalidomide in Subjects with Relapsed/Refractory Follicular Lymphoma," sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco"), was successfully held in Harbin.

2026-04-23

ImmuneOnco’s Subcutaneous IMM2510S IND Application Accepted, Pioneering a New Era of Bispecific Drug Delivery

This milestone marks a critical step in the formulation optimization of the IMM2510 program, promising a superior treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.